Clinical Trials | October 13, 2025
Moderna’s mRNA-4359 shows promising early results in resistant Melanoma at ESMO 2025
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
SkinMedica redefines luxury skincare with reimagined packaging and new HA5 hydra collagen water burst moisturizer
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
The initiative successfully demonstrates that used medical plastic packaging can be recycled and transformed back into new, contact-sensitive medical packaging
WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
Subscribe To Our Newsletter & Stay Updated
